Isorhynchophylline enhances Nrf2 and inhibits MAPK pathway in cardiac hypertrophy
- 37 Downloads
Isorhynchophylline (IRN) is one of the major tetracyclic oxindole alkaloids found in Uncaria rhynchophylla. Studies have found that IRN has diverse biological activities including antioxidant, anti-apoptosis, and neuroprotection. However, little is known about the effect of IRN on the development of cardiac hypertrophy. In this study, we investigated the change of the cell surface area and nascent protein synthesis of cultured H9c2 cardiomyocytes on exposure to phenylephrine (PE) plus IRN, and thus confirmed that IRN ameliorated cardiomyocyte hypertrophy induced by PE in vitro. Meanwhile, it turns out that IRN is also effective in neonatal rat ventricular myocytes (NRVMs) stimulated with angiotensin II (AngII). We also showed that IRN prevented cardiac dysfunction in mice with pressure overload due to transverse aortic constriction (TAC) and attenuated cardiac hypertrophy and fibrosis. IRN treatment improved the cardiac function assessed by echocardiographic parameters fractional shortening (FS) as well as suppressed the cardiac hypertrophy phenotypes, such as the increasing of ventricular mass/body weight and myocyte cross-sectional area. RT-PCR analysis showed that IRN treatment also alleviated the expression of fetal genes of ANP, BNP, Myh7, and the correlated fibrosis genes including TGF-β1, collagen I, collagen III, and CTGF in vivo. Meanwhile, IRN had anti-oxidative effects on cardiac remodeling with suppressed 4-HNE and MDA. Western blot analysis showed that the Nrf2 nuclear translocation and MAPK pathway were involved in the potential mechanisms of IRN on cardiac hypertrophy inhibition. The results of our study provide further evidence that IRN is a promising drug for the treatment of cardiac hypertrophy.
KeywordsIsorhynchophylline Cardiac hypertrophy Remodeling Oxidative stress Fibrosis
YT Zhang and YQ Cui contributed equally to this work. HP Guo, J Wang, and DW Wu conceived and designed research. YT Zhang, S Dai, H Wang, and WD Qin conducted all experiments. W Deng and HN Yang analyzed data. YT Zhang and YQ Cui wrote the manuscript. H Liu and JF Yue carried out data interpretation and discussion. All authors read and approved the manuscript.
This work was supported by grants from the National Natural Science Foundation of China (No. 81300459; No. 81300162), Natural Science Foundation of Shandong Province (No. ZR2016HM48). Project funded by China Postdoctoral Science Foundation (No. 2018T110694; No. 2017M610429; No. 2014M551921) and the International Postdoctoral Exchange Fellowship Program.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
All animal experiments were performed in accordance with the guidelines for the care and use of laboratory animals, published by the Ministry of the People’s Republic of China, and were approved by the Institutional Animal Care and Use Committee of Shandong University.
- Howden R (2013) Nrf2 and cardiovascular defense. Oxidative Med Cell Longev 2013:104308Google Scholar
- Lee H, Baek SH, Lee JH, Kim C, Ko JH, Lee SG, Chinnathambi A, Alharbi SA, Yang WM, Um JY, Sethi G, Ahn KS (2017) Isorhynchophylline, a potent plant alkaloid, induces apoptotic and anti-metastatic effects in human hepatocellular carcinoma cells through the modulation of diverse cell signaling cascades. Int J Mol Sci 18(5)Google Scholar
- Wu JB, Zhou Y, Liang CL, Zhang XJ, Lai JM, Ye SF, Ouyang H, Lin J, Zhou JY (2017) Cyclovirobuxinum D alleviates cardiac hypertrophy in hyperthyroid rats by preventing apoptosis of cardiac cells and inhibiting the p38 mitogen-activated protein kinase signaling pathway. Chin J Integr Med 23:770–778CrossRefGoogle Scholar